Drug Trial Radar · NCT04421495
Safety and Effectiveness of Delamanid-containing Regimen for MDR-TB Patients in China
Last checked: Nov 19, 2026Latest source record: Jul 7, 2022 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
608
Actual
Start
Jul 16, 2020
Primary completion
Jun 16, 2022
Study completion Jul 16, 2024
Sponsor
- Lead sponsor
- Beijing Chest HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 9, 2020
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to monitor and evaluate the safety and effectiveness of Delamanid in combination with an optimal background regimen (OBR) of anti-TB drugs for treatment of MDR-TB.
Conditions
- Multidrug Resistant Tuberculosis
Interventions
DelamanidDrug
the eligible patients will be give damanid-containing regimen
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants experiencing all-cause mortalityTime frame: from enrollment to the completion of the trial ,an average of 30-32months
- Proportion of participants experiencing treatment-emergent AEsTime frame: the whole treatment phase,an average of 18-20 months
Locations
25 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital, Capital Medical University
Beijing, China
Changsha Central Hospital
Changsha, China
Public Health Clinical Center of Chengdu
Chengdu, China
Chongqing Infectious Disease Medical Center
Chongqing, China
Fuzhou Pulmonary Hospital of Fujian
Fuzhou, China
Guangzhou Chest Hospital
Guangzhou, China
Guiyang Public Health Clinical Center
Guiyang, China
Heilongjiang Province center for tuberculosis Control and Prevention
Haerbin, China
Hangzhou Red Cross Hospital
Hangzhou, China
Jiamusi Tumor Hospital
Jiamusi, China
Tuberculosis Hospital in Jilin Province
Jilin City, China
Shandong Provincial Chest Hospital
Jinan, China
The Third People's Hospital of Kunming City
Kunming, China
Lanzhou Pulmonary Hospital
Lanzhou, China
Longtan Hospital of Guangxi Zhuang Autonomous Region
Liuzhou, China
Jiangxi Chest (Third People) Hospital
Nanchang, China
Shanghai Pulmonary Hospital
Shanghai, China
Hebei Chest Hospital
Shijiangzhuang, China
The Fifth People Hospital of Suzhou
Suzhou, China
The Fourth People's Hospital of Taiyuan
Taiyuan, China
Wuhan Institute For Tuberculosis Control
Wuhan, China
Wuhan Jinyintan Hospital
Wuhan, China
Shanxi Provincial Tuberculosis Institute
Xi'an, China
Xi'an Chest Hospital
Xi'an, China
Henan Provincial Chest Hospital
Zhengzhou, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.